S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
NASDAQ:SPRO

Spero Therapeutics - SPRO Stock Forecast, Price & News

$1.85
+0.02 (+1.09%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.81
$1.87
50-Day Range
$1.55
$2.00
52-Week Range
$0.68
$12.04
Volume
95,983 shs
Average Volume
329,919 shs
Market Capitalization
$64.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

Spero Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
242.3% Upside
$6.33 Price Target
Short Interest
Healthy
1.90% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.80
Upright™ Environmental Score
News Sentiment
0.96mentions of Spero Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.48) to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

116th out of 1,055 stocks

Pharmaceutical Preparations Industry

48th out of 518 stocks


SPRO stock logo

About Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

H.C. Wainwright Remains a Buy on Spero Therapeutics (SPRO)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Spero Therapeutics, Inc. (SPRO)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Earnings Outlook For Spero Therapeutics
Spero Therapeutics to Present Data at IDWeek 2022
This Infection-Fighting Biotech Is Recovering Nicely
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
See More Headlines
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Company Calendar

Last Earnings
11/14/2022
Today
1/31/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+242.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-89,760,000.00
Net Margins
-1,162.35%
Pretax Margin
-1,162.35%

Debt

Sales & Book Value

Annual Sales
$17.67 million
Book Value
$2.73 per share

Miscellaneous

Free Float
33,538,000
Market Cap
$64.87 million
Optionable
Optionable
Beta
0.79

Key Executives

  • Dr. Ankit  Mahadevia M.D.Dr. Ankit Mahadevia M.D. (Age 42)
    MBA, Co-Founder, Pres, CEO & Director
    Comp: $924.28k
  • Mr. Satyavrat Shukla C.F.A. (Age 51)
    CFO & Treasurer
    Comp: $788.84k
  • Ted Jenkins
    VP & Head of Investor Relations
  • Ms. Tamara Lynn Joseph L.L.M. (Age 60)
    Chief Legal Officer
  • Mr. James P. Brady
    Chief Human Resource Officer
  • Mr. Timothy Keutzer (Age 55)
    Chief Devel. Officer
  • Dr. Ian A. Critchley
    Head of Clinical Microbiology
  • Dr. Susannah Walpole Ph.D.
    Head of Clinical Operations
  • Dr. Angela Talley M.D.
    Sr. VP of Clinical Devel.
  • Dr. Kamal Hamed M.B.A.
    M.D., M.P.H., Chief Medical Officer













SPRO Stock - Frequently Asked Questions

Should I buy or sell Spero Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRO shares.
View SPRO analyst ratings
or view top-rated stocks.

What is Spero Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued 12-month price objectives for Spero Therapeutics' shares. Their SPRO share price forecasts range from $5.00 to $8.00. On average, they anticipate the company's share price to reach $6.33 in the next twelve months. This suggests a possible upside of 242.3% from the stock's current price.
View analysts price targets for SPRO
or view top-rated stocks among Wall Street analysts.

How have SPRO shares performed in 2023?

Spero Therapeutics' stock was trading at $1.73 at the beginning of the year. Since then, SPRO shares have increased by 6.9% and is now trading at $1.85.
View the best growth stocks for 2023 here
.

Are investors shorting Spero Therapeutics?

Spero Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 667,900 shares, a decline of 21.4% from the December 31st total of 849,400 shares. Based on an average daily trading volume, of 617,400 shares, the short-interest ratio is presently 1.1 days.
View Spero Therapeutics' Short Interest
.

When is Spero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our SPRO earnings forecast
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) issued its quarterly earnings results on Monday, November, 14th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.01. The business earned $2.01 million during the quarter, compared to analyst estimates of $6.75 million. Spero Therapeutics had a negative trailing twelve-month return on equity of 186.94% and a negative net margin of 1,162.35%.

Is Spero Therapeutics a good dividend stock?

Spero Therapeutics (NASDAQ:SPRO) pays an annual dividend of $0.06 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for SPRO.

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ankit Mahadevia, Aquilo Capital Management, Llc, Cristina Larkin and Sath Shukla.
View institutional ownership trends
.

How do I buy shares of Spero Therapeutics?

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spero Therapeutics' stock price today?

One share of SPRO stock can currently be purchased for approximately $1.85.

How much money does Spero Therapeutics make?

Spero Therapeutics (NASDAQ:SPRO) has a market capitalization of $64.87 million and generates $17.67 million in revenue each year. The company earns $-89,760,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis.

How many employees does Spero Therapeutics have?

The company employs 146 workers across the globe.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The official website for the company is sperotherapeutics.com. The company can be reached via phone at (857) 242-1600 or via email at ir@sperotherapeutics.com.

This page (NASDAQ:SPRO) was last updated on 2/1/2023 by MarketBeat.com Staff